JD Health International (HKG:6618) recorded a profit attributable to the owners of 4.16 billion yuan in 2024, 94% higher than 2.14 billion yuan from 2023, a Thursday Hong Kong bourse filing said.
The earnings per share were 1.32 yuan, compared with 0.68 yuan per share from a year earlier.
The digital health services company's revenue for the year came in at 58.2 billion yuan, 8.6% higher than 53.5 billion yuan of the preceding year.
The increase in revenue is attributed to an increase in revenue from the sales of pharmaceutical and healthcare products resulting from an increase in active user accounts, additional purchases, and the increase in online product sales.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.